Methods and compositions for inducing protective immunity against rsv infection

Abstract

Compositions, vaccines and methods using adenovirus vectors for inducing protective immunity against a respiratory syncytial virus (RSV) infection are described.

What is claimed is: 
     
         1 . A method of inducing an immune response against RSV in a subject in need thereof, the method comprising:
 (i) administering to the subject a first composition comprising an immunologically effective amount of a first replication-incompetent adenovirus serotype 26 (Ad26) vector comprising a nucleic acid encoding an RSV F protein having the amino acid sequence of SEQ ID NO: 1 or 2; and   (ii) administering to the subject a second composition comprising an immunologically effective amount of a second replication-incompetent Ad26 vector comprising a nucleic acid encoding the RSV F protein,   wherein the second composition is administered 1-12 weeks after the first composition is administered.   
     
     
         2 . The method of  claim 1 , wherein each of the first replication-incompetent Ad26 vector and the second replication-incompetent Ad26 vector comprises the nucleic acid encoding the RSV F protein having the amino acid sequence of SEQ ID NO: 1. 
     
     
         3 . The method of  claim 1 , wherein each of the first replication-incompetent Ad26 vector and the second replication-incompetent Ad26 vector comprises the nucleic acid having the polynucleotide sequence of SEQ ID NO: 3 or SEQ ID NO: 4. 
     
     
         4 . The method of  claim 3 , wherein each of the first replication-incompetent Ad26 vector and the second replication-incompetent Ad26 vector comprises the nucleic acid having the polynucleotide sequence of SEQ ID NO: 3. 
     
     
         5 . The method of  claim 1 , wherein the second composition is administered 2-10 weeks after the first composition is administered. 
     
     
         6 . The method of  claim 1 , wherein the second composition is administered 4-8 weeks after the first composition is administered. 
     
     
         7 . The method according to  claim 1 , further comprising:
 (iii) administering to the subject a third composition comprising an immunologically effective amount of an adenovirus vector comprising a nucleic acid encoding an antigenic RSV protein.   
     
     
         8 . The method according to  claim 7 , wherein the adenovirus vector in the third composition comprises a nucleic acid encoding the RSV F protein. 
     
     
         9 . The method of  claim 8 , wherein the third composition is administered 4 weeks or 8 weeks after the first composition is administered. 
     
     
         10 . The method of  claim 1 , wherein the subject is 0-8 weeks of age, 12-24 months of age, or 18-50 years of age. 
     
     
         11 . A method of inducing an immune response against RSV in a subject in need thereof, the method comprising:
 (i) administering to the subject a first composition comprising an immunologically effective amount of a first replication-incompetent Ad26 vector comprising a nucleic acid encoding an RSV F protein, wherein the nucleic acid has the polynucleotide sequence of SEQ ID NO: 3 or SEQ ID NO: 4; and   (ii) administering to the subject a second composition comprising an immunologically effective amount of a second replication-incompetent Ad26 vector comprising a nucleic acid encoding the RSV F protein,   wherein the second composition is administered 1-12 weeks after the first composition is administered.   
     
     
         12 . The method of  claim 11 , wherein the second composition is administered 2-10 weeks after the first composition is administered. 
     
     
         13 . The method of  claim 11 , wherein the second composition is administered 4-8 weeks after the first composition is administered. 
     
     
         14 . The method according to  claim 11 , further comprising:
 (iii) administering to the subject a third composition comprising an immunologically effective amount of an adenovirus vector comprising a nucleic acid encoding an antigenic RSV protein.   
     
     
         15 . The method according to  claim 14 , wherein the adenovirus vector in the third composition comprises a nucleic acid encoding the RSV F protein. 
     
     
         16 . The method of  claim 15 , wherein the third composition is administered 4 weeks or 8 weeks after the first composition is administered. 
     
     
         17 . The method of  claim 11 , wherein the subject is 0-8 weeks of age, 12-24 months of age, or 18-50 years of age. 
     
     
         18 . A method of inducing an immune response against RSV in a subject in need thereof, the method comprising:
 (i) administering to the subject a first composition comprising an immunologically effective amount of a first replication-incompetent Ad26 vector comprising a nucleic acid encoding an RSV F protein having the amino acid sequence of SEQ ID NO: 1 or 2;   (ii) administering to the subject a second composition comprising an immunologically effective amount of a second replication-incompetent Ad26 vector comprising a nucleic acid encoding the RSV F protein, wherein the second composition is administered 2-10 weeks after the first composition is administered; and   (iii) administering to the subject a third composition comprising an immunologically effective amount of a third replication-incompetent Ad26 vector comprising a nucleic acid encoding the RSV F protein, wherein the third composition is administered 4 weeks or 8 weeks after the first composition is administered.   
     
     
         19 . The method of  claim 18 , wherein each of the first replication-incompetent Ad26 vector, the second replication-incompetent Ad26 vector, and the third replication-incompetent Ad26 vector comprises the nucleic acid having the polynucleotide sequence of SEQ ID NO: 3 or SEQ ID NO: 4. 
     
     
         20 . The method of  claim 19 , wherein the subject is 0-8 weeks of age, 12-24 months of age, or 18-50 years of age.